Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
6.57
+0.18 (2.82%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.

Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.

The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.

In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.

Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc.
Abeona Therapeutics logo
Country United States
IPO Date Sep 19, 1980
Industry Biotechnology
Sector Healthcare
Employees 84
CEO Vishwas Seshadri

Contact Details

Address:
6555 Carnegie Avenue, 4th Floor
Cleveland, Ohio 44103
United States
Phone 646 813 4701
Website abeonatherapeutics.com

Stock Details

Ticker Symbol ABEO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000318306
CUSIP Number 00289Y107
ISIN Number US00289Y2063
Employer ID 83-0221517
SIC Code 2834

Key Executives

Name Position
Dr. Vishwas Seshadri M.B.A., Ph.D. President, Chief Executive Officer and Director
Joseph Walter Vazzano CPA Chief Financial Officer
Dr. Brendan M. O'Malley J.D., Ph.D. Senior Vice President and General Counsel
Brian Kevany Ph.D. Senior Vice President, Chief Technology Officer and CSO
Gregory Gin Vice President of Investor Relations and Corporate Communications
Alison Hardgrove Chief People Officer
Jon Voss Vice President and Head of Quality
Dr. Madhav Vasanthavada M.B.A., Ph.D. Senior Vice President, Chief Commercial Officer and Head of Business Development
Carl Denny Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Oct 29, 2024 8-K Current Report
Oct 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 14, 2024 8-K Current Report
Aug 12, 2024 10-Q Quarterly Report
Aug 12, 2024 8-K Current Report
Jul 9, 2024 8-K Current Report
Jun 21, 2024 424B5 Filing
Jun 20, 2024 EFFECT Notice of Effectiveness
Jun 17, 2024 S-3/A [Amend] Registration statement under Securities Act of 1933
Jun 17, 2024 144 Filing